FIA
PLRX icon

FNY Investment Advisers’s Pliant Therapeutics PLRX Stock Holding History

FNY Investment Advisers’s Portfolio PLRX Stock Details PLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-25,400
Closed -$37K – 1352
2025
Q3 		$37K Buy
+25,400
New +$38.8K 0.01% 562

Other funds holding PLRX

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $1.26B AUM 60.23% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

FNY Investment Advisers's PLRX Position: Q4 2025 in Review

FNY Investment Advisers sold out of Pliant Therapeutics (PLRX) in Q4 2025, closing a stake of 25,400 shares — an estimated $37K sold.

FNY Investment Advisers first reported a position in PLRX in Q3 2025 and held it in 1 quarter. The position peaked at $37K in Q3 2025. 97 funds tracked by Wall St. Rank hold PLRX as of Q4 2025.

  • FNY Investment Advisers reported no remaining Pliant Therapeutics position as of Q4 2025 after selling out during the quarter.
  • FNY Investment Advisers sold 25,400 Pliant Therapeutics shares in Q4 2025, an estimated $37K.
  • FNY Investment Advisers first reported a position in Pliant Therapeutics in Q3 2025 and held it in 1 quarter.
  • FNY Investment Advisers's Pliant Therapeutics position peaked at $37K in Q3 2025.
  • 97 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q4 2025.

Based on FNY Investment Advisers's 13F filing for Q4 2025, filed 16 Jan 2026.